Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518658 · ClinicalTrials.gov registry record
BlueSync Field Evaluation
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- 257
- Enrollment target
NCT03518658: Completed study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT03518658 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 257 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03518658 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- 257 participants
- Enrollment target
Study Summary
The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.
Primary Outcome
To assess CareLink transmission compliance (adherence to scheduled transmission), the primary objective is to compare the percentages of the CareLink quarterly scheduled transmissions that are completed within the prescribed window during the 12-month follow-up after the baseline visit in the CareLink Database between the evaluation patients who use the MyCareLink Heart™ (MCL) app and patients with low power devices and CareLink monitors 2490 (excluding wireless model 2490C). For both patient gr
Interventions
- OTHER Evaluation Group
- OTHER Control Group (Historical)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2019-12-29 |
What the finished NCT03518658 record still lists
NCT03518658 is an observational study that tracks outcomes without assigning an intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Evaluation Group is the first listed.
NCT03518658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03518658 about?
NCT03518658 is a clinical study titled "BlueSync Field Evaluation". The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.
What is the current status of trial NCT03518658?
This trial is currently completed. The enrollment target is 257 participants. The study started on 2018-04-02. Estimated completion is 2019-12-29.
What interventions are being tested in trial NCT03518658?
The interventions under investigation include: Evaluation Group (OTHER), Control Group (Historical) (OTHER).
Who is sponsoring clinical trial NCT03518658?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI